Differences in vessel healing following delivery of everolimus or paclitaxel: A comparative experimental study using identical stent and biodegradable polymer platforms

EuroIntervention

Volumn 10, Issue 6, 2014, Pages 724-731

  Buszman, Piotr P ^a,b   Milewski, Krzysztof ^a   Pająk, Jacek ^b   Jelonek, Michał ^a   Orlik, Bartłomiej ^a   Krauze, Agata ^a   Gwiazdowska Nowotka, Beata ^c   Wojakowski, Wojciech ^a   Tellez, Armando ^d   Granada, Juan F ^d   Buszman, Paweł E ^a  

^a American Heart of Poland   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c Balton Ltd   (Poland)

^d CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

Biodegradable polymer; Everolimus eluting stent; Paclitaxel eluting stent; Porcine coronary model

Indexed keywords

EVEROLIMUS; PACLITAXEL;

ANGIOCARDIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; BARE METAL STENT; BLOOD VESSEL HEALING; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY; DOUBLE BLIND PROCEDURE; DRUG ELUTING STENT; ENDOTHELIALIZATION; HEALING; HISTOPATHOLOGY; INFLAMMATION; NEOINTIMA; NEOINTIMAL THICKNESS; NONHUMAN; PORCINE MODEL; VASCULAR ENDOTHELIUM;

EID: 84908296631     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV10I6A125     Document Type: Article

References (26)

1. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299:1903-13.
2. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Juni P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372:1163-73.
3. Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Juni P, Schomig A, Windecker S, Kastrati A. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISARTEST 4, and LEADERS randomized trials. Eur Heart J. 2012;33:1214-22.
4. Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Juni P. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimuseluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet. 2011;378:1940-8.
5. Huibregtse B, Pennington D. Differential neointimal response to the implantation of coronary bare metal and everolimus-eluting stents in familial hypercholesterolemic swine. J Am Coll Cardiol. 2010;56;B53.
6. Meredith IT, Verheye S, Dubois CL, Dens J, Fajadet J, Carrie D, Walsh S, Oldroyd KG, Varenne O, El-Jack S, Moreno R, Joshi AA, Allocco DJ, Dawkins KD. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J Am Coll Cardiol. 2012;59:1362-70.
7. Buszman PP, Orlik B, Trela B, Milewski K, Kozlowski M, Pruski M Jr, Drzewiecki J, Peppas A, Granada JF, Kaluza GL, Buszman PE. Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: insights from a multicenter, propensity score-matched registry. Catheter Cardiovasc Interv. 2013;82:E155-62.
8. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375:201-9.
9. Achremczyk M. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Kardiol Pol. 2012;70:762-3.
10. Institute of Laboratory Animal Resources NRC. Principles of care of laboratory animals. NIH Publication. 1996; No. 85-23.
11. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267-74.
12. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31:224-30.
13. Schwartz RS, Edelman E, Virmani R, Carter A, Granada JF, Kaluza GL, Chronos NA, Robinson KA, Waksman R, Weinberger J, Wilson GJ, Wilensky RL. Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv. 2008;1:143-53.
14. Kim JS, Wallace-Bradley D, Alviar CL, Conditt G, Milewski K, Afari ME, Cheng Y, Gallego C, Tellez A, Stone GW, Kaluza GL, Granada JF. Correlation of angiographic late loss with neointimal proliferation in stents evaluated by OCT and histology in porcine coronary arteries. JACC Cardiovasc Imaging. 2011;4:1002-10.
15. Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, Schulz S, Pache J, Fusaro M, Seyfarth M, Schömig A, Mehilli J; Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Investigators. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J. 2009;30:2441-9.
16. Buszman P, Milewski K, Zurakowski A, Pajak J, Liszka L, Musiol E, AbuSamra M, Trznadel S, Kaluza G. Novel biodegradable polymer-coated, paclitaxel-eluting stent inhibits neointimal formation in porcine coronary arteries. Kardiol Pol. 2010;68:503-9.
17. Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC, Llanos G, Dooley J, Falotico R. Long-term effects of polymer-based, slow-release, sirolimuseluting stents in a porcine coronary model. Cardiovasc Res. 2004;63:617-24.
18. Scheller B, Grandt A, Wnendt S, Lorenz G, Bohm M, Nickenig G. Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model. Z Kardiol. 2005;94:445-52.
19. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355:2113-24.
20. Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119:2986-94.
21. Speck U, Cremers B, Kelsch B, Biedermann M, Clever YP, Schaffner S, Mahnkopf D, Hanisch U, Bohm M, Scheller B. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? Circ Cardiovasc Interv. 2012;5:392-400.
22. Milewski K, Zurakowski A, Pajak J, Liszka L, Debinski M, Buszman PP, Samra MA, Dominek P, Aboodi MS, Kaluza GL, Buszman P. Effects of local intracoronary paclitaxel delivery using the Remedy transport catheter on neointimal hyperplasia after stent implantation in a porcine model. Cardiovasc Revasc Med. 2011;12:82-9.
23. Drachman DE. Drug-eluting stents in animals and patients: where do we stand today? Circulation. 2009;120:101-3.
24. Wilson GJ, Huibregtse BA, Stejskal EA, Crary J, Starzyk RM, Dawkins KD, Barry JJ. Vascular response to a third generation everolimus-eluting stent. EuroIntervention. 2010;6:512-9.
25. Verheye S, Martinet W, Kockx MM, Knaapen MW, Salu K, Timmermans JP, Ellis JT, Kilpatrick DL, De Meyer GR. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol. 2007;49:706-15.
26. Trznadel S, Buszman PP, Milewski K, Król M, Gorycki B, Janusz P, Zurakowski A, Wojakowski W, Buszman PE. Everolimus versus paclitaxel eluting biodegradable polymer coated stents for coronary revascularisation: clinical and angiographic results from the pivotal randomised trial. Eur Heart J. 2013;34:P3050.